Heartflow CMO Rogers Sells $261k in Stock, Largest Insider Sale Since Q4
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
heartflowinsider-trading
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Campbell Rogers, Chief Medical Officer of Heartflow, sold $261,266 worth of company common stock on May 20, 2026. The transaction was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission. This sale represents the largest documented disposal of shares by a named executive officer at the cardiovascular diagnostics firm since a $310,000 transaction executed by CEO John Stevens in December 2025. Heartflow stock closed the trading session at $4.75 per share.
Insider sales at medtech firms often receive heightened scrutiny due to the capital-intensive nature of the sector and its reliance on long regulatory pathways. The transaction coincides with a period of sector-wide pressure on growth stocks as the Federal Reserve maintains its benchmark rate at 5.50%. The 10-year Treasury yield sits at 4.45%, creating a higher hurdle for future earnings valuations across the healthcare technology spectrum.
This specific sale follows a significant corporate catalyst. Heartflow announced on May 15, 2026, a $50 million strategic investment from Philips to co-develop next-generation coronary artery disease software. The partnership aims to integrate Heartflow's FFRct analysis into Philips' interventional cardiology suite. The capital injection immediately preceded Rogers' stock sale by five trading days.
Prior comparable transactions provide necessary context. The last major insider sale at Heartflow occurred on December 12, 2025, when CEO John Stevens liquidated $310,000 worth of shares. That sale represented the first major executive transaction after the company's reverse stock split in November 2025, a move designed to regain compliance with Nasdaq listing requirements.
The transaction details show Rogers sold 55,000 shares at a weighted average price of $4.75 per share. This sale reduced his direct holdings by approximately 18%, leaving him with 252,000 shares directly owned. The $261,266 gross proceeds represent a significant liquidity event for the executive. Heartflow's current market capitalization stands at approximately $715 million, based on 150.5 million shares outstanding.
| Metric | Before Sale (Approx.) | After Sale (Approx.) |
|---|---|---|
| Rogers' Direct Holdings | 307,000 shares | 252,000 shares |
| Value of Sold Position | $261,266 | $0 |
| % of Direct Position Sold | 100% of this block | 18% of total direct holdings |
Peer comparison reveals varying insider activity across the digital health sector. Teladoc Health reported zero insider sales by its C-suite in the last 90 days. Nano-X Imaging reported four small sales by its CFO totaling $120,000 in April 2026. Heartflow's year-to-date stock performance is -3.5%, underperforming the iShares U.S. Medical Devices ETF (IHI), which is up 5.2% for the same period.
The sale's primary impact is likely confined to Heartflow's investor sentiment, with a negative near-term influence on stock momentum. Second-order effects could benefit competing coronary diagnostic platforms. Companies like Cleerly, which uses AI for coronary plaque analysis, may see incremental investor interest as capital reallocates within the niche. KeyBanc analysts estimate Cleerly could capture 1-2% market share in the $1.2 billion coronary diagnostic software market if Heartflow's execution falters.
A significant counter-argument exists. Rogers' sale was executed pursuant to a Rule 10b5-1 trading plan, likely adopted months prior. Such plans allow executives to schedule sales in advance to avoid accusations of trading on non-public information. The existence of a plan dampens the signal of immediate negative sentiment, though it does not eliminate market perception risk.
Positioning data from options markets shows a recent increase in put volume for Heartflow. Open interest for $4.50 puts expiring in June 2026 rose by 3,200 contracts in the two days following the sale disclosure. This suggests some institutional desks are establishing downside protection or short positions, anticipating near-term share price pressure in the $4.25-$4.50 support range.
Market participants will watch Heartflow's Q2 2026 earnings report, scheduled for August 8, 2026. The report will provide the first financial results reflecting the initial impact of the Philips partnership. Analysts surveyed by Bloomberg expect revenue of $24.5 million and an adjusted EPS loss of $0.12. The key metric will be guidance on software adoption rates in European markets.
Technical levels are critical. Heartflow stock faces immediate resistance at its 50-day moving average of $4.95. A sustained break above this level on high volume would negate the bearish signal from the insider sale. Conversely, a breach of the $4.25 support level, established in late April 2026, could trigger a decline toward the $3.80 zone where the 200-day moving average currently resides.
The next major catalyst is the American Heart Association Scientific Sessions, scheduled for November 15-18, 2026. Heartflow has historically presented new clinical data at this conference. Positive data readouts on the prognostic value of its FFRct technology could reverse any negative sentiment stemming from insider transactions. The absence of new data would be viewed negatively.
A Rule 10b5-1 trading plan is a pre-arranged schedule for buying or selling securities. Executives adopt these plans during open trading windows to avoid accusations of insider trading. The plan mandates trades on specific dates or at specific price points, regardless of subsequent material non-public information. Rogers' sale was executed under such a plan, which was likely established in Q1 2026. This mechanism provides a legal defense but does not change the market's aggregate supply of shares.
Insider sales in the medtech sector typically carry a stronger signal than in other industries due to long product cycles. The average holding period for an executive's sold shares in medtech is 18 months, compared to 12 months in the broader technology sector. This suggests executives accumulate stock over longer development timelines. Sales often cluster around major financing events or regulatory milestones, as executives diversify personal wealth after protracted periods of illiquid, equity-based compensation.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.